.png/:/)
.png/:/)
The only patented technology that stabilizes acidic cannabinoids for pharmaceutical, wellness, and consumer applications.
Mingowood Pharmacal’s patented Intercalyx™ platform solves the instability problem that has blocked acidic cannabinoid therapeutics for decades. Patented. Scalable. Regulatory-friendly.
Patented formulation technology ready for licensing. Pharmaceutical-grade excipients. No new chemical entities. Scalable from lab to commercial production.
Solve your CBDA, THCA, and CBGA shelf-life problem. Temperature-resilient. Precise dosing. Versatile delivery formats.
Patented platform technology at the intersection of cannabinoid science and pharmaceutical drug delivery. Led by the team behind FDA-approved Ryanodex.
Mingowood Pharmacal is a specialty pharmaceutical company that develops and licenses patented formulation technology for acidic cannabinoids. Our Intercalyx™ platform enables stable, scalable, and regulatory-compliant cannabinoid formulations across pharmaceutical, wellness, and consumer applications. We are actively seeking licensing partners in combination therapy development. Contact us to start the conversation.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.